All In Biotech

Drug Trial Radar · NCT06431971

Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease: A Randomized, Placebo-controlled, Double-blinded, Parallel 2-arm, With Open-label Extension Placebo-to-active Switch, Multi-centre Phase I/IIa Trial

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Dec 2027

Study completion Jul 2028

Sponsor

Lead sponsor
InnoMedica Schweiz AGIndustry
Sponsor type
Industry
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is double-blinded placebo controlled followed by an open-label extension placebo-to-active switch to estimate the efficacy of Talineuren. The investigational Medicinal Product (IMP) is administrated 48 times intravenously as an add-on therapy to the standard of care Parkinson medication. Talineuren is a liposomal formulation containing GM1 (monosialotetrahexosylganglioside) as the pharmacological active substance. The results of this pilot study are essential for the sample size calculation of a subsequent larger phase II/III trial.

Conditions

  • Parkinson Disease

Interventions

  • TalineurenDrug

    Talineuren infusion weekly

  • PlaceboDrug

    Placebo infusion weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Movement Disorder Society Unified Parkinson's Disease Rating Scale scoreTime frame: Baseline, week 25 (primary endpoint)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Neurologisches Institut Konolfingen

    Konolfingen, Switzerland

  • Kantonsspital Aarau (KSA), Neurologische Klinik

    Aarau, Canton of Aargau, Switzerland

  • Hôpitaux Universitaires de Genève (HUG), Département des Neurosciences cliniques NEUCLI, Service de Neurologie

    Geneva, Canton of Geneva, Switzerland

  • Health Ostschweiz/ Kantonsspital St. Gallen (KSSG), Klinik für Neurologie

    Sankt Gallen, Canton of St. Gallen, Switzerland

  • Centre hospitalier universitaire Vaudois (CHUV), Clinical Neurosciences Department

    Lausanne, Canton of Vaud, Switzerland

  • Bellevue Medical Group AG (BMG), Neurozentrum Seefeld

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.